Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series
Purpose: To compare the incidence, type, interval for reactivation, and structural outcomes in infants with aggressive retinopathy of prematurity (A-ROP) treated with ranibizumab or bevacizumab. Method: It is a single-center, retrospective, consecutive, case series. We included infants with A-ROP wh...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/IJO.IJO_161_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556773338611712 |
|---|---|
| author | Anil Babanrao Gangwe Chibuzo B Ekumankama Abhishek Singh Swapnil Madhukar Parchand Deepshikha Agrawal Raj Vardhan Azad |
| author_facet | Anil Babanrao Gangwe Chibuzo B Ekumankama Abhishek Singh Swapnil Madhukar Parchand Deepshikha Agrawal Raj Vardhan Azad |
| author_sort | Anil Babanrao Gangwe |
| collection | DOAJ |
| description | Purpose:
To compare the incidence, type, interval for reactivation, and structural outcomes in infants with aggressive retinopathy of prematurity (A-ROP) treated with ranibizumab or bevacizumab.
Method:
It is a single-center, retrospective, consecutive, case series. We included infants with A-ROP which were initially treated with either intravitreal ranibizumab (IVR, 0.25 mg) or intravitreal bevacizumab (IVB, 0.625 mg) between January 2017 and December 2023. The infants were followed up for reactivation. The demographic and clinical data were collected. The time, zone, type of reactivation, its treatment, type of final structural outcome, and factors associated with reactivation were analyzed.
Results:
One hundred eight among the 322 infants with A-ROP were included in the study. Fifty-five received IVR, while 53 received IVB. Infants treated with IVR had higher incidence of reactivation (92.7% vs 52.8%, P < 0.001) at an earlier interval than IVB (7.7 weeks vs 12.8 weeks, P < 0.001). Infants treated with IVR had approximately 3.3 times higher possibility of reactivation than those treated with IVB. Three infants (5.9%) in the IVR group and five (9.4%) in the IVB group attained complete vascularization of the retina (P = 0.72). More infants treated with IVB had regression with a persistent avascular retina (PAR) than IVR (52.8% vs 15.7%, P < 0.001). Infants in the IVB group had 10 times higher possibility of regression with PAR.
Conclusion:
Infants of A-ROP treated with IVR have a higher incidence and earlier reactivation, while those treated with IVB have less incidence and delayed reactivation, albeit with a higher possibility of regression with a PAR. |
| format | Article |
| id | doaj-art-1db57fa38747429ab9e41c264a096107 |
| institution | Kabale University |
| issn | 0301-4738 1998-3689 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj-art-1db57fa38747429ab9e41c264a0961072025-01-07T06:28:38ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892025-01-0173Suppl 1S119S12510.4103/IJO.IJO_161_24Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case seriesAnil Babanrao GangweChibuzo B EkumankamaAbhishek SinghSwapnil Madhukar ParchandDeepshikha AgrawalRaj Vardhan AzadPurpose: To compare the incidence, type, interval for reactivation, and structural outcomes in infants with aggressive retinopathy of prematurity (A-ROP) treated with ranibizumab or bevacizumab. Method: It is a single-center, retrospective, consecutive, case series. We included infants with A-ROP which were initially treated with either intravitreal ranibizumab (IVR, 0.25 mg) or intravitreal bevacizumab (IVB, 0.625 mg) between January 2017 and December 2023. The infants were followed up for reactivation. The demographic and clinical data were collected. The time, zone, type of reactivation, its treatment, type of final structural outcome, and factors associated with reactivation were analyzed. Results: One hundred eight among the 322 infants with A-ROP were included in the study. Fifty-five received IVR, while 53 received IVB. Infants treated with IVR had higher incidence of reactivation (92.7% vs 52.8%, P < 0.001) at an earlier interval than IVB (7.7 weeks vs 12.8 weeks, P < 0.001). Infants treated with IVR had approximately 3.3 times higher possibility of reactivation than those treated with IVB. Three infants (5.9%) in the IVR group and five (9.4%) in the IVB group attained complete vascularization of the retina (P = 0.72). More infants treated with IVB had regression with a persistent avascular retina (PAR) than IVR (52.8% vs 15.7%, P < 0.001). Infants in the IVB group had 10 times higher possibility of regression with PAR. Conclusion: Infants of A-ROP treated with IVR have a higher incidence and earlier reactivation, while those treated with IVB have less incidence and delayed reactivation, albeit with a higher possibility of regression with a PAR.https://journals.lww.com/10.4103/IJO.IJO_161_24aggressive posterior retinopathy of prematurityaggressive retinopathy of prematurityanti-vegfbevacizumab ranibizumabreactivationretinopathy of prematurity |
| spellingShingle | Anil Babanrao Gangwe Chibuzo B Ekumankama Abhishek Singh Swapnil Madhukar Parchand Deepshikha Agrawal Raj Vardhan Azad Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series Indian Journal of Ophthalmology aggressive posterior retinopathy of prematurity aggressive retinopathy of prematurity anti-vegf bevacizumab ranibizumab reactivation retinopathy of prematurity |
| title | Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series |
| title_full | Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series |
| title_fullStr | Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series |
| title_full_unstemmed | Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series |
| title_short | Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series |
| title_sort | comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity a retrospective case series |
| topic | aggressive posterior retinopathy of prematurity aggressive retinopathy of prematurity anti-vegf bevacizumab ranibizumab reactivation retinopathy of prematurity |
| url | https://journals.lww.com/10.4103/IJO.IJO_161_24 |
| work_keys_str_mv | AT anilbabanraogangwe comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries AT chibuzobekumankama comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries AT abhisheksingh comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries AT swapnilmadhukarparchand comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries AT deepshikhaagrawal comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries AT rajvardhanazad comparisonofreactivationbetweenranibizumabandbevacizumabinaggressiveretinopathyofprematurityaretrospectivecaseseries |